© Reuters. Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration taken June 30, 2018. REUTERS/Russell Boyce/Illustration
(Reuters) – Swiss generic and biosimilar manufacturer Sandoz (SIX:) on Thursday said it had entered into a $265 million settlement agreement in a price-fixing case in the United States.
The company said its U.S. subsidiaries had agreed to pay $265 million in a lawsuit with a class of direct drug purchasers, an agreement that does not contain any admission of wrongdoing by the Swiss company.